84355-10-2Relevant articles and documents
Recyclable alkylated Ru(bpy)32+ complex as a visible-light photoredox catalyst for perfluoroalkylation
Zhang, Xiaodan,Li, Yaming,Hao, Xinyu,Jin, Kun,Zhang, Rong,Duan, Chunying
, p. 1742 - 1748 (2018)
A recyclable Ruthenium tris [4,4′-bis (dinonylmethyl)-2,2′-bipyridine] (Ru[(DNM)2bpy]32+) photocatalyst (PC) was synthesized. Hexane-phase-selective solubility allowed its simple and efficient separation from reaction products via solvent extraction. The excellent catalytic activity and recoverability were demonstrated in batch and flow perfluoroalkylation reactions of coumarin under visible-light irradiation. High reaction rates and easy reusability of the catalyst make this approach attractive for large-scale applications.
Regioselective C-H Trifluoromethylation of Aromatic Compounds by Inclusion in Cyclodextrins
Lu, Xu,Kawazu, Ryohei,Song, Jizhou,Yoshigoe, Yusuke,Torigoe, Takeru,Kuninobu, Yoichiro
supporting information, p. 4327 - 4331 (2021/05/26)
A regioselective radical C-H trifluoromethylation of aromatic compounds was developed using cyclodextrins (CDs) as additives. The C-H trifluoromethylation proceeded with high regioselectivity to afford the product in good yield, even on the gram scale. In the presence of CDs, some substrates underwent a single trifluoromethylation selectively, whereas mixtures of single- and double-trifluoromethylated products were formed in the absence of the CD. 1H NMR experiments indicated that the regioselectivity was controlled by the inclusion of a substrate inside the CD cavity.
5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
-
Paragraph 0454, (2021/05/14)
The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.